Diverse HIV-1 escape pathways from broadly neutralizing antibody PGDM1400 in humanized mice

References

• McCoy LE. The expanding array of HIV broadly neutralizing antibodies. Retrovirology. 2018;15(1):70. doi:https://doi.org/10.1186/s12977-018-0453-y.
   PubMed Web of Science ®Google Scholar
• van Gils MJ, Sanders RW. In vivo protection by broadly neutralizing HIV antibodies. Trends Microbiol. 2014;22(10):550–7. doi:https://doi.org/10.1016/j.tim.2014.08.006.
   PubMed Web of Science ®Google Scholar
• van der Velden YU, Villaudy J, Siteur-van Rijnstra E, van der Linden CA, Frankin E, Weijer K, Schermer E, Vink MA, Berkhout B, Sanders RW, et al. Short communication: protective efficacy of broadly neutralizing antibody PGDM1400 against HIV-1 challenge in humanized mice. AIDS Res Human Retroviruses. 2018;34(9):790–93. doi:https://doi.org/10.1089/aid.2018.0114.
   PubMed Web of Science ®Google Scholar
• Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathogens. 2009;5(5):e1000433. doi:https://doi.org/10.1371/journal.ppat.1000433.
   PubMed Web of Science ®Google Scholar
• Deruaz M, Moldt B, Le KM, Power KA, Vrbanac VD, Tanno S, Ghebremichael MS, Allen TM, Tager AM, Burton DR, et al. Protection of humanized mice from repeated intravaginal HIV challenge by passive immunization: a model for studying the efficacy of neutralizing antibodies in vivo. J Infect Dis. 2016;214(4):612–16. doi:https://doi.org/10.1093/infdis/jiw203.
   PubMed Web of Science ®Google Scholar
• Stoddart CA, Galkina SA, Joshi P, Kosikova G, Long BR, Maidji E, Moreno ME, Rivera JM, Sanford UR, Sloan B, et al. Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice. Virology. 2014;462-463:115–25. doi:https://doi.org/10.1016/j.virol.2014.05.036.
   PubMed Web of Science ®Google Scholar
• Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, Mouquet H, Spatz LA, Diskin R, Abadir A, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature. 2012;492(7427):118–22. doi:https://doi.org/10.1038/nature11604.
   PubMed Web of Science ®Google Scholar
• Julg B, Liu PT, Wagh K, Fischer WM, Abbink P, Mercado NB, Whitney JB, Nkolola JP, McMahan K, Tartaglia LJ, Borducchi EN, Khatiwada S, Kamath M, LeSuer JA, Seaman MS, Schmidt SD, Mascola JR, Burton DR, Korber BT, Barouch DH, et al. Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. Science Transationall Medicine. 2017;9(408). doi:https://doi.org/10.1126/scitranslmed.aao4235
   Google Scholar
• Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP Jr., Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522(7557):487–91. doi:https://doi.org/10.1038/nature14411.
   PubMed Web of Science ®Google Scholar
• Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF, Murrell B, Pfeifer N, Nogueira L, Oliveira TY, et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat Med. 2017;23(2):185–91. doi:https://doi.org/10.1038/nm.4268.
   PubMed Web of Science ®Google Scholar
• Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME, Salantes DB, Seamon CA, Scheinfeld B, Kwan RW, et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. New Eng J Med. 2016;375(21):2037–50. doi:https://doi.org/10.1056/NEJMoa1608243.
   PubMed Web of Science ®Google Scholar
• Mendoza P, Gruell H, Nogueira L, Pai JA, Butler AL, Millard K, Lehmann C, Suárez I, Oliveira TY, Lorenzi JCC, et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature. 2018;561(7724):479–84. doi:https://doi.org/10.1038/s41586-018-0531-2.
   PubMed Web of Science ®Google Scholar
• Sok D, van Gils MJ, Pauthner M, Julien J-P, Saye-Francisco KL, Hsueh J, Briney B, Lee JH, Le KM, Lee PS, et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc Nat Acad Sci. 2014;111(49):17624–29. doi:https://doi.org/10.1073/pnas.1415789111.
   PubMed Web of Science ®Google Scholar
• Xu L, Pegu A, Rao E, Doria-Rose N, Beninga J, McKee K, Lord DM, Wei RR, Deng G, Louder M, et al. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science. 2017;358(6359):85–90. doi:https://doi.org/10.1126/science.aan8630.
   PubMed Web of Science ®Google Scholar
• Julg B, Tartaglia LJ, Keele BF, Wagh K, Pegu A, Sok D, Abbink P, Schmidt SD, Wang K, Chen X, Joyce MG, Georgiev IS, Choe M, Kwong PD, Doria-Rose NA, Le K, Louder MK, Bailer RT, Moore PL, Korber B, Seaman MS, Abdool Karim SS, Morris L, Koup RA, Mascola JR, Burton DR, Barouch DH, et al. Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Sci Trans Med. 2017;9(406). doi:https://doi.org/10.1126/scitranslmed.aal1321
   Google Scholar
• Hessell AJ, Haigwood NL. Animal models in HIV-1 protection and therapy. Curr Opinion HIV AIDS. 2015;10(3):170–76. doi:https://doi.org/10.1097/COH.0000000000000152.
   PubMed Web of Science ®Google Scholar
• McCoy LE, Falkowska E, Doores KJ, Le K, Sok D, van Gils MJ, Euler Z, Burger JA, Seaman MS, Sanders RW, et al. Incomplete neutralization and deviation from sigmoidal neutralization curves for HIV broadly neutralizing monoclonal antibodies. PLoS Pathogens. 2015;11(8):e1005110. doi:https://doi.org/10.1371/journal.ppat.1005110.
   PubMed Web of Science ®Google Scholar
• Webb NE, Montefiori DC, Lee B. Dose–response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies. Nat Commun. 2015;6(1):8443. doi:https://doi.org/10.1038/ncomms9443.
   PubMed Web of Science ®Google Scholar
• Lee JH, Andrabi R, Su C-Y, Yasmeen A, Julien J-P, Kong L, Wu NC, McBride R, Sok D, Pauthner M, et al. A broadly neutralizing antibody targets the dynamic HIV envelope trimer apex via a long, rigidified, and anionic β-hairpin structure. Immunity. 2017;46(4):690–702. doi:https://doi.org/10.1016/j.immuni.2017.03.017.
   PubMed Web of Science ®Google Scholar
• Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lu C-L, Lorenzi JC, Feldmann A, Braunschweig M, Nogueira L, Oliveira T, et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature. 2016;535(7613):556–60. doi:https://doi.org/10.1038/nature18929.
   PubMed Web of Science ®Google Scholar
• Andrabi R, Voss JE, Liang C-H, Briney B, McCoy LE, Wu C-Y, Wong C-H, Poignard P, Burton D. Identification of common features in prototype broadly neutralizing antibodies to HIV envelope V2 apex to facilitate vaccine design. Immunity. 2015;43(5):959–73. doi:https://doi.org/10.1016/j.immuni.2015.10.014.
   PubMed Web of Science ®Google Scholar
• Cale EM, Gorman J, Radakovich NA, Crooks ET, Osawa K, Tong T, Li J, Nagarajan R, Ozorowski G, Ambrozak DR, Asokan M, Bailer RT, Bennici AK, Chen X, Doria-Rose NA, Druz A, Feng Y, Joyce MG, Louder MK, O'Dell S, Oliver C, Pancera M, Connors M, Hope TJ, Kepler TB, Wyatt RT, Ward AB, Georgiev IS, Kwong PD, Mascola JR, Binley JM, et al. Virus-like particles identify an HIV V1V2 apex-binding neutralizing antibody that lacks a protruding loop. Immunity. 2017;46:777–91 e10.
   PubMed Web of Science ®Google Scholar
• Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014;509(7498):55–62. doi:https://doi.org/10.1038/nature13036.
   PubMed Web of Science ®Google Scholar
• Doria-Rose NA, Georgiev I, O’Dell S, Chuang G-Y, Staupe RP, McLellan JS, Gorman J, Pancera M, Bonsignori M, Haynes BF, et al. A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. J Virol. 2012;86(15):8319–23. doi:https://doi.org/10.1128/JVI.00696-12.
   PubMed Web of Science ®Google Scholar
• Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH, Korber B, et al. HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design. Cell Host Microbe. 2019;26:296. doi:https://doi.org/10.1016/j.chom.2019.07.016.
   PubMed Web of Science ®Google Scholar
• Torrents de la Pena A, Rantalainen K, Cottrell CA, Allen JD, van Gils MJ, Torres JL, Crispin M, Sanders RW, Ward AB, et al. Similarities and differences between native HIV-1 envelope glycoprotein trimers and stabilized soluble trimer mimetics. PLoS Pathogens. 2019;15(7):e1007920. doi:https://doi.org/10.1371/journal.ppat.1007920.
   PubMed Web of Science ®Google Scholar
• Lynch RM, Boritz E, Coates EE, DeZure A, Madden P, Costner P, Enama ME, Plummer S, Holman L, Hendel CS, et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Trans Med. 2015;7:319r a206. doi:https://doi.org/10.1126/scitranslmed.aad5752.
   Web of Science ®Google Scholar
• de Taeye SW, Ozorowski G, Torrents de la Pena A, Guttman M, Julien J-P, van den Kerkhof TGM, Burger J, Pritchard L, Pugach P, Yasmeen A, et al. Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes. Cell. 2015;163(7):1702–15. doi:https://doi.org/10.1016/j.cell.2015.11.056.
   PubMed Web of Science ®Google Scholar
• van den Kerkhof TL, de Taeye SW, Boeser-Nunnink BD, Burton DR, Kootstra NA, Schuitemaker H, Sanders RW, van Gils MJ. HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds. Retrovirology. 2016;13(1):48. doi:https://doi.org/10.1186/s12977-016-0279-4.
   PubMed Web of Science ®Google Scholar